Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. The agency is now heavily scrutinizing Phase 1 and 2 studies to see whether they identify the safest and most effective dose—while this change seems abrupt, it’s loomed over the field for a long time.
We’ve helped our clients adapt to the new standards with five best practices outlined in this article.
Related Insights
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Related Insights
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023